Background: Multidrug chemotherapy (CT) is still associated with relevant side-effects. We assessed, under current practice patterns, frequency and severity of CT-induced toxicity and its economic consequences.
patients' quality of life [8] , toxicity management has considerable economic impact, particularly in the inpatient setting [9, 10] .
For European health care systems and especially for Germany, microeconomic data on supportive care interventions are scarce [11, 12] . The existing health economic literature, mainly studies from the United States, focuses on particular toxic effects such as anaemia [11, 13] , febrile neutropenia (FN) [7, 14, 15] , thrombocytopenia and bleeding [16, 17] , mucositis [18] and CT-induced nausea and vomiting [2] . However, information on the cumulative cost of toxicity management, e.g. per treatment cycle, is not available.
In an environment of flat-rate reimbursement and high pressure on health care budgets, clinicians and policy makers need to understand the global impact of toxicity management on costs, not only to optimise current supportive care strategies original article but also to use more effective and less toxic CTs. In this context, real-word data can serve as cost estimates in health economic modelling [19] . Moreover, knowledge of the actual cost of supportive care permits comparison with flat-rate reimbursement, which is not necessarily fully cost covering [9, 20] . Also, the heterogeneity of (haemato) toxicity has been studied widely in the past decade [7, 21] . Individualised approaches to allocate expensive preventive measures seem necessary to optimise supportive care strategies in the future. For patient subgroups with high toxicity treatment cost, prophylaxis is presumably very cost effective. Therefore, identifying and characterising these patients seems important.
As a result, we prospectively assessed, under current practice pattern, the occurrence of CT-induced toxicity and its impact on health resource utilisation and costs. Our second goal was to identify patient subgroups with high costs imputable to toxicity management. As supportive care issues are especially large in non-small-cell lung cancer (NSCLC) and lymphoproliferative disorder (LPD) patients receiving several cycles of multidrug (immuno-) CT [22, 23] , consecutive recruitment was restricted to this group of patients.
patients and methods

study design and patient selection
This prospective, longitudinal, multicentre observational cohort study was conducted from January 2005 to June 2007 in two university and two regular care hospitals in Germany. Centres were required to be experienced in the administration of CT, including the prevention and management of CT-induced complications, and to operate at all levels of current hospital cancer care.
Patients were eligible if they were assigned to first-or second-line (immuno-) CT for NSCLC or LPD [non-Hodgkin's lymphoma, Hodgkin's lymphoma, multiple myeloma, chronic lymphocytic leukaemia (CLL)]. Patients were enrolled consecutively; recurrent enrolment was possible. The observation period was the length of one CT line (see following for definition).
To avoid inclusion of patients whose CT was only initiated at study site, but continued elsewhere, patients had to be scheduled for at least two CT visits. Patients receiving myeloablative CT with stem cell support were excluded, as were those who were not able to participate in patient interviews due to linguistic or cognitive reasons.
Written informed consent was obtained from all patients; the study was approved by the ethics committees of Technische Universität München and Ludwig-Maximilians-Universität München.
Medical and economic data were collected from preplanned comprehensive chart reviews and patient interviews. Chart data were abstracted by trained staff of the hospital pharmacy of Klinikum rechts der Isar. Data collection was standardised using a data manual.
One hospital CT visit was defined as CT application on ‡1 consecutive days, followed by a ‡7-day CT-free interval. The length of one CT cycle as well as the number of CT visits per cycle varied according to CT regimen. One CT line was defined as the period from the start to the scheduled end or discontinuation due to tumour progression or toxicity.
patient characteristics
Patient baseline characteristics extracted from medical charts included the following: demographics, clinical history and comorbidity, cancer diagnosis and CT regimen.
Comorbidities of heart, lung, pancreas, liver and kidney and thromboembolic events as well as Eastern Cooperative Oncology Group (ECOG) performance were analysed to indicate patients overall health status at enrolment.
Tumour stage was classified using the TNM (tumour-node-metastasis) and Mountain classification for NSCLC, the Ann Arbor system for non-Hodgkin's lymphoma and Hodgkin's disease, and the Durie-Salmon staging system for multiple myeloma. CLL stage was described according to Rai. Therefore, Binet stage A was transformed to Rai stage 0. None of the CLL patients had tumour stage higher than Binet A.
evaluation of toxicity
Occurrence and severity of CT-induced toxicity were recorded at each CT visit or by telephone after the final CT visit according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0 and the causality criteria of the World Health Organisation (WHO) Uppsala Monitoring Centre [24] . Frequency of toxic effects was aggregated per treatment cycle. Toxic effects were surveyed using a structured interview form.
In case of fever, outpatients were advised to undergo assessment of haematological counts at least on a weekly basis. If blood cell count nadir monitoring was provided by external institutions, a written request to disclose blood cell count nadirs was transmitted via the patient.
FN was incorporated into the analysis as a composed variable. FN was defined as fever ‡38°C and an absolute neutrophil count (ANC) <1 · 10 9 /l.
If ANC nadir was unavailable, febrile leukopenia (FL) was assessed (leukocyte count <2 · 10 9 /l and fever ‡38°C).
causality rating. Only ADRs according to WHO causality rating (i.e. clinical events with a reasonable temporal relationship to administration of the drug) were considered for analysis [24] .
resource utilisation and costs
Health care consumption due to toxicity was structured as follows:
use of prophylactic or rescue supportive drugs (e.g. antiemetics, colony-stimulating factors, antibiotics, antifungal drugs) use of red blood cell, platelet and plasma transfusions medical procedures, laboratory tests, chest X-rays or other diagnostic procedures number of treatment days for outpatient (ambulatory and daytime clinic) visits (e.g. for blood transfusion), hospitalisation (inpatient overnight admission) or extended hospitalisation (e.g. hospitalisation due to fever); the term 'hospital visit' refers to both outpatient visits and inpatient admissions.
Hospitalisation was considered as extended when the patient was not discharged the day after the last application of (immuno-) CT. With the exception of CT visits postponed because of toxicity, preplanned hospital visits for the purpose of CT administration were not considered; nor were CT agents or health care consumption directly related to CT-induced toxicity (e.g. cancer diagnostics, radiation therapy, surgery).
costs. Cost analysis was conducted from the hospital provider perspective.
Estimates of costs were reported as the quantity of different resources consumed. The overall toxicity management cost per treatment cycle (TMC-TC) comprised the following:
(Prolonged) hospitalisation, outpatient visits due to toxicity: cost of hospitalisation; cost of drugs, medical treatment and diagnostic procedures associated with toxicity management were added on top Hospital visits for CT application: only cost of drugs, medical treatment and diagnostic procedures associated with toxicity management; cost of hospitalisation was considered CT associated and therefore not included in the analysis. One-way sensitivity analysis was carried out by varying cost factors of TMC-TC within the lower and upper limit of their 95% CIs. Moreover, to account for uncertainties caused by applying local cost data (Table 1) to health care resource utilisation data, main cost factors were varied by percentages [25, 26] : drugs (625%) and hospital basic services (+12%; 28%), based on difference between the mean hospital daily cost in Bavaria and in German federal states with minimal and maximal daily hospital cost values in 2007 [27] .
results
patient baseline characteristics
A total of 386 consecutively scheduled CT lines at four study sites were identified according to selection criteria. In 79% (n = 304), patients agreed to participate in the study. Eighteen CT lines had to be excluded from the analysis due to protocol violation, withdrawn informed consent or nonavailability of the patient chart. Overall, 286 CT lines (74%) were evaluable, with a total of 1004 CT cycles corresponding to 1531 CT visits. Thirteen patients were enrolled twice. Hence, the total number of patients was 273. Disposition of study patients is shown in Figure 1 . The 99 non-participants and excluded patients were significantly older (63.9 versus 60.3 years, P = 0.016) and had higher ECOG performance status (ECOG ‡2: 28.3% versus 11%, P < 0.001) compared with the participants. Sex and cancer type were equally distributed (data not shown).
Of the 273 assessable patients, 120 (44%) had NSCLC and 153 (56%) LPD, with 98 of them being non-Hodgkin's lymphoma. A diagnosis of Hodgkin's lymphoma (n = 21), multiple myeloma (n = 26) and CLL (n = 8) was less frequent. Mean patient age was 60.3 years (SD 13.0); 40.3% of patients were at least 65 years old. At first enrolment, 56% of patients had stage >III disease and 11% an ECOG performance status of two or more; 80% of patients had a history of comorbidity. Most frequent comorbidities were heart disease (46.5%), an antecedent of thromboembolic episodes (18.7%) and pulmonary disease (16.5%).
NSCLC patients were significantly older than LPD patients and presented more often with stage III/IV disease, ECOG performance status of two or more, and comorbidities of the heart, lung and thromboembolic events ( Table 2) .
In 76% of CT lines, patients underwent first-line treatment. Twenty-one percent had previously received CT. Seven percent received radiation therapy within 6 weeks before CT and 11% a concomitant radio-CT. Forty-seven percent of CT lines for LPD were CHOP (combination CT with cyclophosphamide, doxorubicin, vincristine and prednisone)-like regimens and 78% of NSCLC lines platinum based. Predisposition to infection due to the presence of central venous catheters or port systems was documented in 22.4% of CT lines.
Mean cycle number per CT line was 3.5. Fifty-eight percent of CT lines for NSCLC and 13% for LPD were not completed as scheduled. The main reason for discontinuation of CT was tumour progression for NSCLC (52%) and toxicity for LPD (45%; Table 3 ). 
consumption of health care resources
Toxicity-associated utilisation of health resources is shown in Table 5 and Figure 2 . Additional hospital visits due to CT-induced toxicity were reported in 371 of 1004 cycles (37%). Inpatient toxicity management was more frequent than outpatient management (25.7% versus 15.4%). In 15.8% of cycles, CT visits were prolonged due to toxicity for a mean duration of 6.5 days. Rehospitalisation due to toxicity was observed in 13% of cycles (mean length of stay: 11.4 days). In 19 cycles (1.9%), an intensive care unit (ICU) stay was necessary. Toxicity-associated use of drugs (prophylactic and rescue medication) was reported in 961 treatment cycles. Most frequently used drugs were antiemetics (95.4%). Antibiotics and/or antifungal drugs were given in 14% and granulocyte colony-stimulating factor support in 5.6% of CT cycles. Blood products including red blood cells, platelets, fresh frozen plasma, albumin and antithrombin III were reported in 27.5% of cycles. Other medical procedures, e.g. haemodialysis, implantation of central venous catheters due to phlebitis, monitoring for infusion reaction and glucocorticoid-induced hyperglycaemia, as well as consultations were necessary in 24.5% of cycles. The most relevant diagnostic procedure was microbiology testing (16%). Imaging and other diagnostic procedures (e.g. echocardiography, pulmonary function) were reported in 13% of cycles.
costs of toxicity management
The average costs per treatment cycle from the perspective of the provider (hospital) are presented in Figure 3 . Mean (median) TMC-TC totalled €1032 (€86; 95% CI €835-1230), with €764 for hospital basic services including staff, which accounted for 74% of total cost, followed by cost of drugs, diagnostics and blood products (€128, €61 and €57), which accounted for 12%, 6% and 6%, respectively. Costs for (par)enteral nutrition and other medical procedures were €6 and €15 (£1%), respectively, per CT cycle.
Although not significant, mean TMC-TC was slightly higher for NSCLC than for LPD patients (€1137 versus €967, respectively). This is mainly due to the higher cost for hospital basic services and staff. More than half of CT cycles involved costs £€100, another 42% of cycles had toxicity-associated costs ranging from €101 to 5000. The remaining 5% of cycles (n = 53) had high costs ( ‡€5000) and generated 56% of total expenses in the observed cohort ( Figure 4) .
subgroup analysis
Subgroup analysis revealed that mean (median) costs are particularly high in cycles involving an ICU stay: €14 121 (€8833; 95% CI €8401-19 842). Costs rose exponentially with the number of grade 3/4 ADRs and were highest in n = 20 cycles affected by more than four ADRs: €10 881 (€5455; 95% CI €4698-17064). They were 34 times higher than in cycles without severe toxicity and accounted for 21% of overall costs (Table 6 ). With €7093 (€4531; 95% CI €5299-8887), cycles affected by grade 3/4 infections were also identified as high-cost cycles compared with €500 (€57; 95% CI €413-588) for cycles without grade 3/4 infections. In cycles affected by at least one FN/FL episode, cost averaged €5170 (€2899; 95% CI €2993-7347), compared with €802 (€71; 95% CI €642-961) for cycles without FN/FL.
sensitivity analysis
Referring to sensitivity analyses, mean TMC-TC (€1032) was most sensitive regarding costs of hospital basic services. When varied according to its specific confidence limits ( Figure 5 ), mean TMC-TC ranged from €890 to €1174 (614%). Mean TMC-TC resulting from changes in various cost determinants were listed in descendent order.
Percental cost modifications of hospital basic services (Table  7) produced very similar results, with mean TMC-TC variation from €971 to €1124 (26%; +9%).
discussion
Pressure on hospital health care budgets is constantly rising. In oncology, financing of innovative expensive therapies and therapy-induced complications with highly variable additional costs poses a special challenge. Therefore, we conducted this study to assess, under current practice patterns, the impact of CT-induced toxicity management on health resource consumption and cost.
impact of toxicity in clinical practice
Frequency data of CT toxicity typically come from randomised, controlled trials with selective recruitment and limited generalisability [28] . In contrast, our study gives an estimate of toxicity frequency in the clinical practice setting. In the observed NSCLC and LPD patient cohort, every second CT If not otherwise stated. b n = 7 missing. c n = 20 missing. d n = 6 not stated, n = 2 other reasons. e n = 26 missing. f n = 6 missing.
CT, chemotherapy; LPD, lymphoproliferative disorder; NSCLC, non-small-cell lung cancer; CHOP, combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone.
original article Annals of Oncology cycle was affected by at least one NCI-CTCAE grade 3/4 toxicity episode. Moreover, 40% of cycles were affected by at least one additional hospital visit or extension of hospitalisation due to toxicity. Therefore, the impact of CT-associated adverse events appears to be substantial both from a clinical and from an economic point of view. Including all prophylactic and therapeutic measures, TMC-TC amounted to >€1000. This translates into an extra cost per patient of €3500 (data not shown).
cost of toxicity management
The bulk of economic literature on supportive care strategies comes from the United States [9, 10] , where costs of a health care intervention usually range substantially higher than in Europe [11, 29, 30] . In contrast, variations between European cost estimates seem to be much lower. With €3841 mean cost per FN episode, the recently published Spanish study is broadly in line with the €4368 incremental TMC-CT attributable to our FN/FL subgroup (€5170 TMC-CT for patients with FN/FL minus €802 for patients without FN/FL). Therefore, the results seem to be transferable or easily adjustable to other health care systems and allow for identical or similar conclusions. To our knowledge, this is the first prospective longitudinal European analysis providing insight into the structure and distribution of TMC-CT.
Since toxicity management was covered mainly by the participating study centres, resource consumption between CT visits (e.g. consultation of a general practitioner) was estimated to be low. Thus, cost analysis was carried out from the hospital provider perspective. Indirect costs were not considered, as earlier German data had shown that the number of additional workdays lost as a result of CT-induced toxicity is low [2] .
Accounting for 70% of the total cost, hospitalisation is the cost driver; drugs and transfusions and other medical procedures produce another 30%. This highlights the fact that cost estimates solely based on the length of hospitalisation lead to an underestimation of true toxicity cost.
health economic impact, clinical implications and further research
With 5% of cycles producing 56% of overall costs, the distribution of TMC-TC is highly asymmetric. As a consequence, mean TMC-TC (€1032) differs broadly from median costs (€86). Typically, mean costs serve as cost estimates in health economic models. Therefore, overestimation of cost -effectiveness could be the consequence. 
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Moreover, in the light of the observed high variability of TMC-TC in daily clinical care, hospital decision makers should interpret alleged differences in assumption-driven cost computations based on label-congruent regimens with caution. In this context, prospective studies or models incorporating observational data should be juxtaposed to Drugs 97 [20] (67-126)
147 [12] ( 128 [14] (98-158) results from purely theoretical approaches like the recently published papers on the cost-effectiveness of pegfilgrastim versus filgrastim before reaching definite conclusions [31] [32] [33] . Similarly, asymmetric distribution of cost has been shown for FN [7] , CT-induced thrombocytopenia and bleeding [16] . As a result, predictors for high TMC-TC should improve cost -effectiveness of current supportive care strategies. As our subgroup analyses reveal, TMC-TC depends on level of care, severity and number of ADRs. In cycles with grade 3/4 ADRs, TMC was 5.5-fold higher than in cycles without grade 3/4 toxicity. Mean TMC-TC cost rose exponentially with the number of grade 3/4 ADRs and was particularly high in cycles with more than four grade 3/4 ADRs (€10 881), ICU stay (€14 121), grade 3/4 infection (€7093) and FN/FL (€5071). Therefore, the reduction of severity grade and number of ADRs, as well as the avoidance of FN/FL and/or infections, are not only prominent clinical aims but also seem to have considerable economic implications. A risk-based approach to supportive care takes into account factors that predispose patients to an increased risk for severe toxic effects. Patient and treatment characteristics such as age, presence of leukaemia, hypovolaemia, comorbidities and infectious complications are associated with increased mortality, length of stay and cost due to FN [7, 34, 35] . Among patients with advanced-stage NSCLC, the pretreatment factors age, gender, performance status and white blood counts were reported to be significant predictors of severe adverse events [36] .
Considerable research is focused on identifying the genetic basis of CT-induced toxicity [37, 38] . Ultimately, these genetic indicators may complement clinical parameters for individualising therapy. In recent years, the concept of toxicity clusters has emerged, suggesting that CT complications do not occur in isolation [39, 40] . Our data seem to support the sharing of a common pathogenesis for clustering toxic effects. 
Further research should describe toxicity clusters of high-cost cycles, as observed in this study, and define pretreatment factors predictive for high TMC. In summary, our results reflect the high variability of CT-induced toxicity management cost in LPD and NSCLC patients. They confirm the value of real-world data to clarify treatment cost composition and distribution. Costs rose exponentially with the number of grade 3/4 ADRs and were particularly high in cycles affected by more than four ADRs, cycles with intensive care, and cycles affected by grade 3/4 infections and FN/FL. Asymmetric cost distribution highlights the need for individualised supportive care strategies. Future research should focus on identifying toxicity clusters and patient characteristics predictive for high costs.
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